(PharmaNewsWire.Com, January 16, 2017 ) The launch of extended half-life drugs in the market is expected to substantially improve the adoption rates, owing to their ability to act for prolonged periods of time. For instance, Heron Therapeutics' SUSTOL and Tesaro's VARUBI offer protection against CINV for five days and seven days, respectively. Additionally, the emergence of oral therapies is expected to enhance the patient compliance, resulting in market growth.
Publisher's analysts forecast the global CINV drugs market to grow at a CAGR of 5.41% during the period 2017-2021. For more information about this report: http://www.reportsweb.com/global-chemotherapy-induced-nausea-and-vomiting-drugs-market-2017-2021 . Covered in this report The report covers the present scenario and the growth prospects of the global CINV drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of CINV drugs.
The market is divided into the following segments based on geography: -Americas -APAC -EMEA
Publisher's report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Market driver -Growing preference of chemotherapy drugs in developing countries -For a full, detailed list, view our report
Market challenge -Growing popularity of alternate therapies for the treatment of cancer in developed countries -For a full, detailed list, view our report
Market trend -Increasing inorganic growth strategies likely to fuel the market growth -For a full, detailed list, view our report
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
